PAI-2/SerpinB2 inhibits proteolytic activity in a P. gingivalis-dominated multispecies bacterial consortium.

[1]  J. Hamilton,et al.  Porphyromonas gingivalis-derived RgpA-Kgp Complex Activates the Macrophage Urokinase Plasminogen Activator System , 2015, The Journal of Biological Chemistry.

[2]  G. Bachrach,et al.  Identification and Characterization of Fusolisin, the Fusobacterium nucleatum Autotransporter Serine Protease , 2014, PloS one.

[3]  Lili Chen,et al.  Protease-activated receptors expression in gingiva in periodontal health and disease. , 2014, Archives of oral biology.

[4]  L. Shapira,et al.  The role of RgpA in the pathogenicity of Porphyromonas gingivalis in the murine periodontitis model. , 2013, Journal of clinical periodontology.

[5]  T. Chuang,et al.  TLR-induced PAI-2 expression suppresses IL-1β processing via increasing autophagy and NLRP3 degradation , 2013, Proceedings of the National Academy of Sciences.

[6]  A. van Belkum,et al.  Highly Specific Protease-Based Approach for Detection of Porphyromonas gingivalis in Diagnosis of Periodontitis , 2011, Journal of Clinical Microbiology.

[7]  C. Cierniewski,et al.  Association of Plasminogen Activator Inhibitor Type 2 (PAI-2) with Proteasome within Endothelial Cells Activated with Inflammatory Stimuli* , 2011, The Journal of Biological Chemistry.

[8]  B. Cochran,et al.  Forty years later and the role of plasminogen activator inhibitor type 2/SERPINB2 is still an enigma. , 2011, Seminars in thrombosis and hemostasis.

[9]  P. Bartold,et al.  Immunohistochemical demonstration of the plasminogen activator system in human gingival tissues and gingival fibroblasts. , 2010, Journal of periodontal research.

[10]  Andreas Suhrbier,et al.  A Physiological Function of Inflammation-Associated SerpinB2 Is Regulation of Adaptive Immunity , 2010, The Journal of Immunology.

[11]  N. Sugano,et al.  Protease-activated receptor 2 mediates interleukin-8 and intercellular adhesion molecule-1 expression in response to Aggregatibacter actinomycetemcomitans. , 2009, Oral microbiology and immunology.

[12]  J. Potempa,et al.  Corruption of Innate Immunity by Bacterial Proteases , 2008, Journal of Innate Immunity.

[13]  M. Hollenberg,et al.  Role of protease‐activated receptors in inflammatory responses, innate and adaptive immunity , 2008, Journal of leukocyte biology.

[14]  J. Enghild,et al.  A New Autocatalytic Activation Mechanism for Cysteine Proteases Revealed by Prevotella intermedia Interpain A* , 2008, Journal of Biological Chemistry.

[15]  K. Izuhara,et al.  Inhibitory Mechanism of a Cross-class Serpin, the Squamous Cell Carcinoma Antigen 1* , 2003, Journal of Biological Chemistry.

[16]  K. Hirai,et al.  Purification and partial characterization of a dipeptidyl peptidase from Prevotella intermedia. , 2003, Oral microbiology and immunology.

[17]  P D Marsh,et al.  Are dental diseases examples of ecological catastrophes? , 2003, Microbiology.

[18]  J. Whisstock,et al.  Evidence that serpin architecture intrinsically supports papain-like cysteine protease inhibition: engineering alpha(1)-antitrypsin to inhibit cathepsin proteases. , 2002, Biochemistry.

[19]  B. Kinnby.  The Plasminogen Activating System in Periodontal Health and Disease , 2002, Biological chemistry.

[20]  M. Baker,et al.  The localization of the relaxed form of plasminogen activator inhibitor type 2 in human gingival tissues , 2001, Histochemistry and Cell Biology.

[21]  J. Potempa,et al.  Role of bacterial proteinases in matrix destruction and modulation of host responses. , 2000, Periodontology 2000.

[22]  L. Matsson,et al.  Localization of plasminogen activators and plasminogen-activator inhibitors in human gingival tissues demonstrated by immunohistochemistry and in situ hybridization. , 1999, Archives of oral biology.

[23]  D. Brömme,et al.  The reactive site loop of the serpin SCCA1 is essential for cysteine proteinase inhibition. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[24]  J. Enghild,et al.  Comparative Properties of Two Cysteine Proteinases (Gingipains R), the Products of Two Related but Individual Genes ofPorphyromonas gingivalis * , 1998, The Journal of Biological Chemistry.

[25]  J. Dickinson,et al.  The Serine Proteinase Inhibitor (Serpin) Plasminogen Activation Inhibitor Type 2 Protects against Viral Cytopathic Effects by Constitutive Interferon α/β Priming , 1998, The Journal of experimental medicine.

[26]  M. Baker,et al.  Immunological Detection of Conformational Neoepitopes Associated with the Serpin Activity of Plasminogen Activator Inhibitor Type-2* , 1998, The Journal of Biological Chemistry.

[27]  J. Dickinson,et al.  The C-D interhelical domain of the serpin plasminogen activator inhibitor-type 2 is required for protection from TNF-α induced apoptosis , 1998, Cell Death and Differentiation.

[28]  L. Matsson,et al.  Aggravation of gingival inflammatory symptoms during pregnancy associated with the concentration of plasminogen activator inhibitor type 2 (PAI-2) in gingival fluid. , 1996, Journal of periodontal research.

[29]  J. Brown,et al.  Molecular characterization of plasminogen activators in human gingival crevicular fluid. , 1995, Archives of oral biology.

[30]  L. Matsson,et al.  The plasminogen-activating system in gingival fluid from adults. An intra-individual study before and after treatment of gingivitis. , 1994, Scandinavian journal of dental research.

[31]  K. Yamamoto,et al.  Purification and characterization of a novel arginine-specific cysteine proteinase (argingipain) involved in the pathogenesis of periodontal disease from the culture supernatant of Porphyromonas gingivalis. , 1994, The Journal of biological chemistry.

[32]  J. Potempa,et al.  Lysine- and arginine-specific proteinases from Porphyromonas gingivalis. Isolation, characterization, and evidence for the existence of complexes with hemagglutinins. , 1994, The Journal of biological chemistry.

[33]  L. Granath,et al.  Tissue plasminogen activator (t-PA) and placental plasminogen activator inhibitor (PAI-2) in gingival fluid from 8-9-year-old children. , 1993, Scandinavian journal of dental research.

[34]  P. Gettins,et al.  Structure and mechanism of action of serpins. , 1992, Hematology/oncology clinics of North America.

[35]  B. Schwartz,et al.  Regulation of plasminogen activator inhibitor mRNA levels in lipopolysaccharide-stimulated human monocytes. Correlation with production of the protein. , 1992, The Journal of biological chemistry.

[36]  D. Beighton,et al.  A scheme for the identification of viridans streptococci. , 1991, Journal of medical microbiology.

[37]  B. Åstedt,et al.  Tissue plasminogen activator and placental plasminogen activator inhibitor in human gingival fluid , 1991 .

[38]  S. Edwardsson,et al.  Identification procedures for oral Actinomyces species. , 1990, Oral microbiology and immunology.

[39]  G. Chao,et al.  Characterization of sodium dodecyl sulfate-stable Bacteroides gingivalis proteases by polyacrylamide gel electrophoresis , 1989, Infection and immunity.

[40]  S. Thorsen,et al.  Kinetics of inhibition of tissue-type and urokinase-type plasminogen activator by plasminogen-activator inhibitor type 1 and type 2. , 1988, European journal of biochemistry.

[41]  S. Thorsen,et al.  Epidermal plasminogen activator inhibitor (PAI) is immunologically identical to placental‐type PAI‐2 , 1988, FEBS letters.

[42]  B. Schwartz,et al.  Increased release of plasminogen activator inhibitor type 2 accompanies the human mononuclear cell tissue factor response to lipopolysaccharide. , 1988, Blood.

[43]  I. Hägerstrand,et al.  Cellular Localisation in Placenta of Placental Type Plasminogen Activator Inhibitor , 1986, Thrombosis and Haemostasis.

[44]  B. Åstedt,et al.  Isolation of a new specific plasminogen activator in hibitor from pregnancy plasma , 1986, British journal of haematology.

[45]  S. Twining.  Fluorescein isothiocyanate-labeled casein assay for proteolytic enzymes. , 1984, Analytical biochemistry.

[46]  L. Holmberg,et al.  An inhibitor from placenta specifically binds urokinase and inhibits plasminogen activator released from ovarian carcinoma in tissue culture. , 1978, Biochimica et biophysica acta.

[47]  T. Kawano,et al.  Partial purification and properties of urokinase inhibitor from human placenta. , 1970, Journal of biochemistry.

[48]  L. Matsson,et al.  Plasminogen activating capacity in gingival fluid from deteriorating and stable periodontal pockets. , 2002, Journal of periodontal research.

[49]  N. Lang,et al.  Increasing expression of tissue plasminogen activator and plasminogen activator inhibitor type 2 in dog gingival tissues with progressive inflammation. , 2001, Archives of oral biology.